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Am J Physiol Gastrointest Liver Physiol 310: G477–G486, 2016. First
published January 28, 2016; doi:10.1152/ajpgi.00444.2015.—Muta-
tions in the PRSS1 gene encoding human cationic trypsinogen are
associated with hereditary and sporadic chronic pancreatitis. High-
penetrance PRSS1 mutations found in hereditary pancreatitis alter
activation and/or degradation of cationic trypsinogen, thereby promot-
ing intrapancreatic trypsinogen activation. In contrast, a number of
rare PRSS1 variants identified in subjects with sporadic chronic
pancreatitis cause misfolding and endoplasmic reticulum (ER) stress.
Mutation p.L104P is unique among natural PRSS1 variants, since it
affects the substrate binding site of trypsin. The aim of the present
study was to establish the clinical significance of variant p.L104P
through functional analysis. We found that p.L104P trypsin exhibited
decreased activity on peptide and protein substrates; however, auto-
activation was slightly accelerated. Remarkably, binding of the phys-
iological trypsin inhibitor serine protease inhibitor Kazal type 1
(SPINK1) was decreased by 70-fold. In the presence of the trypsino-
gen-degrading enzyme chymotrypsin C, mutant p.L104P autoacti-
vated to higher trypsin levels than wild-type trypsinogen. This appar-
ent resistance to degradation was due to slower cleavage at Arg122
rather than Leu81. Finally, secretion of mutant p.L104P from trans-
fected cells was markedly reduced due to intracellular retention and
aggregation with concomitant elevation of ER stress markers. We
conclude that PRSS1 variant p.L104P exhibits a variety of phenotypic
changes that can increase risk for chronic pancreatitis. Mutation-
induced misfolding and associated ER stress are the dominant effects
that support a direct pathogenic role in chronic pancreatitis.
chronic pancreatitis; hereditary pancreatitis; trypsinogen activation;
autoactivation; endoplasmic reticulum stress; misfolding; intracellular
aggregation
CHRONIC PANCREATITIS IS A relapsing progressive inflammatory
disease of the pancreas that often develops on the basis of
genetic predisposition (7, 44). Susceptibility genes identified to
date include, in the order of discovery, PRSS1 (serine protease
1, human cationic trypsinogen), CFTR (cystic fibrosis trans-
membrane conductance regulator), SPINK1 (serine protease
inhibitor Kazal type 1, pancreatic secretory trypsin inhibitor),
CTRC (chymotrypsinogen C), CPA1 (procarboxypeptidase
A1), and CEL (carboxyl ester lipase) (8, 12, 26, 31, 42, 45, 46).
Mutations in PRSS1, such as p.N29I and p.R122H, are strong
risk factors that cause autosomal dominant hereditary pancre-
atitis with incomplete penetrance and variable expressivity
(20). Although less well characterized, CPA1 mutations also
confer strong predisposition resulting in early onset disease
(45). In contrast, risk variants of other genes typically confer
smaller but significant risk and are often found in the trans-
heterozygous state in affected carriers (25). More recently, a
GWAS study identified common variants in the CLDN2 locus
and in the promoter region of PRSS1 that appear to increase
disease risk only by a small degree (10, 43).
Mechanistic studies revealed that mutations in most risk
genes result in premature intrapancreatic trypsinogen activa-
tion. Thus, high-penetrance PRSS1 variants cause higher tryp-
sin levels either by stimulating trypsinogen autoactivation
and/or by inhibiting CTRC-dependent trypsinogen degradation
(13, 33). Loss-of-function mutations in the protective trypsin
inhibitor SPINK1 or the trypsinogen-degrading enzyme CTRC
can also result in elevated trypsin activity (1, 4, 5, 15, 18, 26).
Consistent with the trypsin paradigm, a rapidly autodegrading
variant of PRSS2 encoding human anionic trypsinogen was
shown to protect against chronic pancreatitis (47). Finally,
variants that diminish CFTR function can stimulate trypsino-
gen activation through impaired ductal flushing and/or altered
intraluminal pH (24).
Investigations into the cellular effects of pancreatitis-asso-
ciated mutations revealed an alternative disease mechanism
unrelated to trypsin activity, i.e., mutation-induced protein
misfolding and consequent endoplasmic reticulum (ER) stress
(1, 14, 30, 39, 45). CPA1 mutations and some PRSS1 variants
are most likely to exert their pathogenic effect via this pathway
(14, 30) although misfolding was also observed with a handful
of CTRC (1, 39) and SPINK1 (4, 5, 18) variants, and it may
also underlie the mechanism of action of the recently described
CEL hybrid variant (12). The PRSS1 variants that appeared to
cause misfolding (p.K92N, p.D100H, p.R116C, p.S124F,
p.C139F, p.C139S, p.G208A) were typically rare and found in
sporadic idiopathic cases (14, 30, and references therein).
The c.311TC (p.L104P) human cationic trypsinogen vari-
ant was first reported in three heterozygous carriers of a
German pedigree with a history of abdominal pain and diabetes
but without clinically proven chronic pancreatitis (40). The
same variant was later identified in a subject of Chinese origin
with idiopathic chronic pancreatitis (6). The limited clinical
and genetic data do not allow conclusive determination
whether or not the p.L104P variant is pathogenic. The Leu104
residue forms part of the conserved hydrophobic S2 subsite
(Schechter-Berger nomenclature) (29) of the substrate binding
site of trypsin. Natural PRSS1 variants affecting the substrate
binding site of trypsin have not been described before, and in
this regard variant p.L104P is unique. Therefore, in the present
study, we set out to investigate the biochemical and cellular
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effects of variant p.L104P to confirm or rule out a possible
pathogenic role in chronic pancreatitis.
MATERIALS AND METHODS
Materials. Expression and purification of recombinant CTRC,
CTRB1, CTRB2, CPA1, SPINK1, and ecotin have been described
previously (18, 19, 23, 33, 34, 37, 38, 45).
Nomenclature. Amino acid residues in human cationic trypsinogen
were numbered starting with the initiator methionine of the primary
translation product according to the recommendations of the Human
Genome Variation Society. The reference sequence used was
NM_002769.4.
Plasmid construction and mutagenesis. The pTrapT7 PRSS1,
pTrapT7 intein-PRSS1, and pcDNA3.1() PRSS1 expression plas-
mids were constructed previously (17, 22, 27, 28). Missense mutation
p.L104P was generated by overlap extension PCR mutagenesis and
cloned into the expression plasmids.
Expression and purification of recombinant trypsinogen. Wild-type
and p.L104P cationic trypsinogens were expressed in Escherichia coli
BL21(DE3) as cytoplasmic inclusion bodies (27, 28). For autoactiva-
tion experiments in the presence of CTRC, trypsinogens were ex-
pressed as fusions with a self-splicing mini-intein in the aminopepti-
dase P-deficient LG-3 E. coli strain (16, 17). After self-splicing, this
construct generates homogeneous intact NH2-termini not processed
by cellular aminopeptidases. Refolding and purification of trypsino-
gen on immobilized ecotin was carried out as reported previously
(16). Concentrations of purified trypsinogen preparations were deter-
mined from the ultraviolet absorbance at 280 nm using the extinction
coefficient 37,525 M1·cm1
SPINK1 binding assays. Binding of wild-type and p.L104P mutant
human cationic trypsin to the trypsin inhibitor SPINK1 was charac-
terized by measuring the KD value of the reaction in equilibrium, as
we described previously (32, 35). Trypsin concentrations were deter-
mined by titration against ecotin, and SPINK1 concentration was
determined by titration against wild-type human cationic trypsin.
Wild-type (50 pM) and mutant (500 pM) trypsin were incubated
overnight (for 16 h) with increasing concentrations of the inhibitor
ranging from 0 to 100 pM for wild-type trypsin and 0 to 1,000 pM for
the mutant trypsin. Residual trypsin activity was measured with 150
M N-CBZ-Gly-Pro-Arg-7-amido-4-methylcoumarin in 0.1 M
Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20. The increase
in fluorescence was monitored at 380 nm excitation and 460 nm
emission wavelengths continuously for 10 min at 22°C. The free
protease concentration was plotted as a function of the total inhibitor
concentration, and the experimental points were fitted with the fol-
lowing equation: y E {E x K-sqrt[(E x K)2 4Ex]}/2,
where the independent variable x represents the total inhibitor con-
centration, the dependent variable y is the free protease concentration
in equilibrium, K is KD, and E denotes the total protease concentra-
tion.
Trypsinogen autoactivation. Wild-type and mutant trypsinogen at
the indicated concentration (1 or 2 M) were incubated in the absence
or presence of 5, 10, 25, and 50 nM human CTRC and 10 nM cationic
trypsin in 0.1 M Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween
20 (final concentrations) at 37°C. At given times, 2-l aliquots were
withdrawn and mixed with 48 l assay buffer containing 0.1 M
Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20. Trypsin
activity was measured by adding 150 l of 200 M N-CBZ-Gly-Pro-
Arg-p-nitroanilide substrate and following the release of the yellow
p-nitroaniline at 405 nm in a SpectraMax plus384 microplate reader
(Molecular Devices, Sunnyvale, CA) for 1 min. Reaction rates were
calculated from fits to the initial linear portions of the curves. The
trypsin substrate was dissolved in 0.1 M Tris·HCl (pH 8.0), 1 mM
CaCl2, and 0.05% Tween 20.
Enzyme kinetic analysis. Michaelis-Menten parameters were mea-
sured in 0.1 M Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20
at 22°C using 1–2 nM (wild type) or 2–5 nM (p.L104P) trypsin (final
concentrations). The concentration of the peptide substrates was
varied between 10 and 180 M (wild type) or 40 and 360 M
(p.L104P mutant). Rates of substrate cleavage were plotted as a
function of substrate concentration, and data points were fitted with
the Michaelis-Menten hyperbolic equation. To determine the apparent
inhibitory constant (Ki) of benzamidine, kinetic measurements were
performed in the presence of increasing inhibitor concentrations
(0–80 M). Apparent KM values were plotted as a function of
inhibitor concentration, and Ki was derived from the negative inter-
cept of the linear fit on the horizontal axis.
Cell culture and transfection. Human embryonic kidney (HEK)
293T cells were cultured in six-well tissue culture plates (106 cells/
well) in DMEM supplemented with 10% fetal bovine serum, 4 mM
glutamine, and 1% penicillin/streptomycin solution at 37°C in a
humidified atmosphere containing 5% CO2. Transfections were per-
formed using 4 g pcDNA3.1() PRSS1 plasmid and 10 l Lipo-
fectamine 2000 (Invitrogen) in 2 ml DMEM. After overnight incuba-
tion at 37°C, cells were rinsed and overlaid with 2 ml OptiMEM
medium (Invitrogen). Media and cells were collected 48 h after this
medium change.
Measurement of trypsin activity in conditioned media. Aliquots (50
l) of conditioned media were supplemented with 0.1 M Tris·HCl (pH
8.0) by adding 5 l from a 1 M stock solution and 10 mM calcium by
adding 1 l of a 0.5 M CaCl2 solution. Trypsinogen was then
activated by adding 1 l human enteropeptidase from a 1.4 g/ml
stock solution (R&D Systems, Minneapolis, MN). After incubation
for 1 h at 37°C, 50-l aliquots were removed and mixed with 150 l
of 200 M N-CBZ-Gly-Pro-Arg-p-nitroanilide substrate. Trypsin ac-
tivity was measured as described under Trypsinogen autoactivation.
Preparation of cell lysates. Transfected cells were rinsed two times
with phosphate-buffered saline. Reporter lysis buffer (200 l; Pro-
mega) and 4 l protease inhibitor cocktail (Sigma) were added to each
well, and the cells were scraped and vortexed briefly. After 15 min
incubation on ice, the lysates were cleared by centrifugation. The
protein concentration of the supernatant was measured with a Micro
BCA Protein Assay Kit (Thermo Scientific).
SDS-PAGE and Western blotting. Conditioned media (200 l)
were precipitated with 10% trichloroacetic acid (final concentration),
resuspended in 20 l Laemmli sample buffer containing 100 mM
dithiothreitol, heat-denatured at 95°C for 5 min, and run on 15%
SDS-polyacrylamide gels. The gels were stained with Coomassie blue
R-250. For Western blotting, conditioned media (5 l) or cell lysates
(20 g total protein) were directly mixed with sample buffer and
electrophoresed as described above. Proteins were transferred to
Immobilon-P membranes (Millipore, Bedford, MA) at 350 mA for 1
h. Trypsinogen was detected with a sheep polyclonal antibody (no.
AF3848; R&D Systems) used at a dilution of 1:5,000 followed by
horseradish peroxidase (HRP)-conjugated donkey polyclonal anti-
sheep IgG (no. HAF016; R&D Systems) used at 1:2,000 dilution.
Incubations with primary and secondary antibodies were performed at
room temperature for 1 h each. HRP was detected using the Super-
Signal West Pico Chemiluminescent Substrate (Thermo Scientific).
Reverse transcription-PCR analysis. RNA was isolated from HEK
293T cells transfected with given plasmids using the RNeasy Mini Kit
(Qiagen), and 2 g RNA were reverse-transcribed with the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Semiquantitative measurements of X-box-binding protein 1 (XBP1)
mRNA splicing were performed by PCR using primers that amplify
both the spliced and unspliced forms and generate 441- and 415-bp
amplicons, respectively. XBP1 primers were as follows: sense primer,
5=-CCT TGT AGT TGA GAA CCA GG-3= and antisense primer,
5=-GGG CTT GGT ATA TAT GTG G-3=. The PCR amplicons were
separated by agarose gel electrophoresis, stained with ethidium bro-
mide, and photographed. The fraction of spliced XPB1 was then
determined by densitometry. Levels of immunoglobulin-binding pro-
tein (BiP) mRNA were determined using quantitative PCR with
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TaqMan primers and TaqMan Universal PCR Mastermix (Applied
Biosystems). Gene expression was quantitated using the comparative
CT method (CT method). Expression levels of BiP were first
normalized to those of the glyceraldehyde-3-phosphate dehydroge-
nase internal control gene (CT) and then to expression levels mea-
sured in cells transfected with empty vector (CT). Results were
expressed as fold changes calculated with the formula 2CT.
RESULTS
Modeling the effect of the p.L104P mutation. Position 104 in
human cationic trypsinogen corresponds to amino acid 99 in
the conventional numbering of chymotrypsin-like serine pro-
teases, and it usually harbors aliphatic amino acids such as the
Leu found in human trypsins. This residue helps to shape the
S2 subsite, which is also lined by His63 (chymotrypsin num-
bering His57) and Trp216 (chymotrypsin numbering Trp215).
Although the S2 site is relatively hydrophobic, with the excep-
tion of Asp and Glu, it can accommodate a variety of residues
with little selectivity (3, 11). The side chain of Leu104 can form
van der Waals contacts with the P2 side chain of the bound
substrate or inhibitor, as seen, for example, in the structure of
the Michaelis complex of an inactive bovine trypsin mutant
with the Pittsburgh variant of the 1-antitrypsin inhibitor (Fig.
1) (9). In addition, an H bond between the backbone amino and
carbonyl groups of Leu104 and Asp100 (chymotrypsin number-
ing Asp95) contributes to the H bond network that stabilizes the
loop between Pro97 (chymotrypsin numbering Pro92) and
Asp107 (chymotrypsin numbering Asp102). Mutation of Leu104
to Pro should alter its interactions with the P2 side chain of
substrates and inhibitors and also eliminates the H bond stabi-
lizing the Pro97-Asp107 loop. These changes are expected to
alter substrate and inhibitor binding.
Catalytic activity of p.L104P cationic trypsin. Determination
of the kinetic parameters of the mutant enzyme on small
synthetic substrates N-CBZ-Gly-Pro-Arg-p-nitroanilide and
N-CBZ-Gly-Pro-Arg-7-amido-4-methylcoumarin revealed an
	10-fold decrease in the catalytic efficiency that was mostly
attributable to an increase in the KM (Table 1). Larger protein
substrates were also cleaved less efficiently by the mutant.
Thus, the mutant enzyme activated human chymotrypsinogens
B1, B2 (data not shown), and C 	20-fold slower relative to
wild-type cationic trypsin, whereas activation of human
proCPA1 was reduced by about twofold (Fig. 2). Finally,
mutant p.L104P digested bovine 
-casein at a twofold de-
creased rate (Fig. 3).
Autoactivation of p.L104P cationic trypsinogen. Experi-
ments described above indicate that the p.L104P trypsin
mutant cleaves a variety of substrates at a reduced rate.
Remarkably, however, this was not the case when trypsin-
mediated trypsinogen activation (autoactivation) was tested.
When measured at pH 8.0 in 1 mM calcium, the mutant
trypsinogen autoactivated slightly faster than wild type (Fig.
4A). SDS-PAGE analysis of the autoactivation process con-
firmed more rapid conversion of the p.L04P trypsinogen
band to trypsin compared with wild-type cationic trypsino-
gen (Fig. 4B). Interestingly, the typically seen proteolytic
fragments resulting from cleavage of the Arg122-Val123
peptide bond were much less noticeable in case of the
mutant enzyme, indicating that this autolytic site is poorly
cleaved by p.L104P trypsin (Fig. 4B).
Autoactivation of human cationic trypsinogen is regulated
by CTRC through specific proteolytic cleavages. When auto-
activation of wild-type trypsinogen is measured in the presence
of CTRC, the rate is slightly increased due to processing of the
activation peptide to a shorter form, whereas trypsin levels are
markedly reduced due to trypsinogen degradation (33). This
Leu Trp
His
P2
P1
97-107 loop
Fig. 1. Role of Leu104 in the S2 subsite of the
trypsin substrate binding site. The Michaelis
complex between a catalytically inactive bo-
vine trypsin mutant and the Pittsburgh vari-
ant of 1-antitrypsin is shown (Protein Data
Bank file 1OPH). The side chains contribut-
ing to the S2 subsite of trypsin are shown in
red, and the P1 Arg and P2 Pro residues of
the inhibitor are indicated in green. See text
for details. The broken line indicates an H
bond between the main chain atoms of posi-
tions 104 and 100 that stabilizes the 97–107
loop. The image was rendered by UCFS
Chimera 1.10.2 (www.cgl.ucsf.edu/chimera).
Table 1. Kinetic parameters of wild-type and mutant human
cationic trypsin on the synthetic chromogenic substrate
GPR-pNA and GPR-AMC
kcat, s1 KM, M kcat/KM, M1·s1
GPR-pNA
Wild type 135 5.9 23.9  4.1 5.7  106
p.L104P 64  1.5 118.7  6.4 5.4  105
GPR-AMC
Wild type 99.5 1.3 22.7  1.2 4.4  106
p.L104P 69.7 1.3 208.5  9 3.3  105
Values are means  SD; n  3 experiments. kcat, Catalytic rate constant.
N-CBZ-Gly-Pro-Arg-p-nitroanilide (GPR-pNA) and fluorescent substrate
N-CBZ-Gly-Pro-Arg-7-amido-4-methylcoumarin (GPR-AMC), measured in
0.1 M Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20, at 22oC.
G479CATIONIC TRYPSINOGEN VARIANT p.L104P
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00444.2015 • www.ajpgi.org
 by 10.220.33.5 on January 16, 2017
http://ajpgi.physiology.org/
D
ow
nloaded from
 
latter process requires not only a CTRC-mediated cleavage
after Leu81 in the calcium-binding loop but also an autolytic
cleavage after Arg122. Compared with wild-type cationic
trypsinogen, autoactivation of mutant p.L104P was less af-
fected by CTRC, and the mutant autoactivated to higher trypsin
levels (Fig. 5), e.g., in the presence of 50 nM CTRC, mutant
activity reached	35%, whereas wild type plateaued at 15% of
potential maximal activity. Visualizing the activation reaction
on Coomassie blue-stained gels confirmed the stronger trypsin
bands in the p.L104P mutant and the absence of the proteolytic
fragments due to cleavage at Arg122 (Fig. 5C). Thus, the
apparent resistance of p.L104P trypsinogen to CTRC-mediated
degradation is due to the defective autolytic cleavage of the
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Fig. 2. Effect of mutation p.L104P on the activation of pancreatic proenzymes
by trypsin. A and B: wild-type and mutant human cationic trypsin (25 nM)
were incubated with 2 M human chymotrypsinogen B1 (CTRB1) or chymo-
trypsinogen C (CTRC) in 0.1 M Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05%
Tween 20 (final concentrations) at 37°C. At the indicated times, 2-l aliquots
were removed, and chymotrypsin activity was measured using 150 M
Suc-Ala-Ala-Pro-Phe-p-nitroanilide substrate. C: wild-type and mutant human
cationic trypsin (25 nM) were incubated with 2 M human procarboxypepti-
dase A1 (proCPA1) in 0.1 M Tris·HCl (pH 8.0) and 1 mM CaCl2 (final
concentrations) at 37°C. At the indicated times, 100-l aliquots were precip-
itated with 10% trichloroacetic acid, electrophoresed on 15% SDS-PAGE gels,
and stained with Coomassie blue. CPA1, activated carboxypeptidase A1.
Representative graphs and gel picture from two or three experiments are
shown.
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Fig. 3. Effect of mutation p.L104P on the digestion of bovine 
-casein with
trypsin. Wild-type and mutant human cationic trypsin (2 nM) were incubated
with 
-casein (0.2 mg/ml) in 0.1 M Tris·HCl (pH 8.0) and 1 mM CaCl2 (final
concentrations) at 37°C. At the indicated times, 100-l aliquots were precip-
itated with 10% trichloroacetic acid, electrophoresed on 15% SDS-PAGE gels,
and stained with Coomassie blue. A representative gel from two experiments
is shown.
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Fig. 4. Effect of mutation p.L104P on autoactivation of trypsinogen. Wild-type
and mutant human cationic trypsinogen (2 M) were incubated with 10 nM
initial trypsin in 0.1 M Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20
(final concentrations) at 37°C. A: at the indicated times 2-l aliquots were
removed, and trypsin activity was measured with 150 M N-CBZ-Gly-Pro-
Arg-p-nitroanilide substrate as described in MATERIALS AND METHODS. Trypsin
activity was converted to active trypsin concentration using the maximal
plateau activity as the 2 M reference value. B: autoactivation was also
followed by SDS-PAGE. At the indicated times, 100-l aliquots were precip-
itated with 10% trichloroacetic acid, electrophoresed on 15% SDS-PAGE gels,
and stained with Coomassie blue. *Two chains of trypsin cleaved at the Arg122
autolytic site. Representative graph and gel from three experiments are shown.
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Arg122-Val123 peptide bond (see also Fig. 4B). This conclusion
was supported by direct digestion experiments with CTRC that
demonstrated no change in cleavage of the Leu81-Glu82 peptide
bond in p.L104P trypsinogen relative to wild type (Fig. 6).
Binding of SPINK1 trypsin inhibitor to p.L104P trypsin. The
physiological inhibitor SPINK1 binds with high affinity to
cationic trypsin. In equilibrium-binding assays, we determined
a KD value of 3.9  0.4 (SE) pM (n  3). In contrast, SPINK1
bound to mutant p.L104P with a KD of 284  56 (SE) pM
(n  3), indicating a 70-fold decreased affinity as a result of
less favorable S2–P2 interactions (Fig. 7). As a control exper-
iment, we also measured inhibition by the small-molecule
trypsin inhibitor benzamidine, which binds to the primary
specificity pocket of trypsin and does not make extended
subsite contacts. Wild-type and p.L104P mutant trypsin were
inhibited by benzamidine with Ki values of 32 and 42 M,
respectively, indicating that mutation p.L104P has no signifi-
cant effect on the primary binding pocket of trypsin (reviewed
but not shown).
Secretion of p.L104P trypsinogen. To study the effect of the
p.L104P mutation on cellular secretion of trypsinogen, we
transiently transfected HEK 293T cells with expression plas-
mids carrying wild-type and mutant cationic trypsinogen
cDNA. Although 293T cells do not have a regulated secretory
pathway as acinar cells, this cell line has been exceedingly
useful to characterize mutation-induced misfolding and secre-
tion defects, since these cells do not secrete endogenous
proteins to a significant level and, unlike acinar cells, can be
transfected using expression plasmids with high efficiency (14,
30). Secretion of cationic trypsinogen in the incubation me-
dium was measured by SDS-PAGE, Western blot, and activity
assays (Fig. 8). Remarkably, all three approaches indicated that
A
B
Tr
yp
si
no
ge
n 
(µ
M
)
0 2 4 6 8 10
0
0.5
1.0
1.5
2.0
Time (min)
wild type
p.L104P
kDa
wild type
0 2 5 10 min
p.L104P
0 2 5 10_40 _35
_25
_15
_10
Intact Tg
Cleaved Tg
Fig. 6. Effect of mutation p.L104P on the cleavage of the Leu81-Glu82 peptide
bond in trypsinogen (Tg) by CTRC. Wild-type and mutant human cationic
trypsinogen (2 M) were incubated with 25 nM human CTRC in 0.1 M
Tris·HCl (pH 8.0) (final concentrations) at 37°C. A: at the indicated times,
100-l reactions were precipitated with 10% trichloroacetic acid (final con-
centration) and analyzed by SDS-PAGE and Coomassie blue staining. B:
densitometric evaluation of the intensity of the intact trypsinogen bands.
Representative gel from three experiments is shown. Error bars were omitted
for clarity; the error was within 10% of the mean.
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Fig. 5. Effect of mutation p.L104P on autoactivation of trypsinogen in the
presence of chymotrypsin C (CTRC). Wild-type (A) and mutant (B) human
cationic trypsinogen (1 M) were incubated in the absence or presence of the
indicated concentrations of human CTRC and 10 nM cationic trypsin in 0.1 M
Tris·HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20 (final concentrations) at
37°C. At the indicated times, 2-l aliquots were removed, and trypsin activity
was measured as described in MATERIALS AND METHODS. Trypsin activity was
expressed as percentage of the maximal activity measured in the absence of
CTRC. C: autoactivation in the presence of 10 nM CTRC was also followed
by SDS-PAGE. At the indicated times, 150-l aliquots were precipitated with
10% trichloroacetic acid, electrophoresed on 15% SDS-PAGE gels, and
stained with Coomassie blue. The faint proteolytic fragment observed in the
wild-type sample at 15 kDa corresponds to the COOH-terminal chain of
trypsin cleaved at the Arg122 autolytic site. Representative graph and gel from
two experiments are shown.
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secretion of the p.L104P mutant was markedly reduced. As
judged by the trypsin activity measured in the medium after
enteropeptidase activation, the extent of the secretion defect
was about ninefold relative to wild type (Fig. 8C).
To address the cause of the secretion defect, we used
Western blot to detect trypsinogen in cell lysates. The amount
of intracellular trypsinogen was comparable in cells transfected
with wild-type and p.L104P trypsinogen constructs, indicating
that the mutant enzyme is translated normally but becomes
intracellularly retained, most likely due to misfolding in the ER
(Fig. 9A). To determine whether aggregation could play a role
in intracellular retention, we separated the insoluble trypsino-
gen fraction by ultracentrifugation of cell lysates. Insoluble
trypsinogen was recovered only in the pellet of lysates from
cells expressing p.L104P mutant but not from cells expressing
wild-type trypsinogen, demonstrating that the mutant enzyme
is more prone to aggregation intracellularly (Fig. 9B).
ER stress in HEK 293T cells expressing p.L104P
trypsinogen. The apparent secretion defect and intracellular
aggregation of mutant p.L104P suggest the possibility of mis-
folding-induced ER stress, as we observed previously with
other mutant digestive enzymes (1, 30, 36, 39, 45). To test for
ER stress, we examined mRNA levels of the ER chaperon BiP
and analyzed the inositol-requiring enzyme 1 (IRE1)-mediated
mRNA splicing of the transcription factor XBP1. Both ER
stress markers were significantly elevated in cells expressing
p.L104P trypsinogen (Fig. 10).
DISCUSSION
In the present study we investigated the functional effects of
the p.L104P PRSS1 variant to determine whether this rare
variant might play a pathogenic role in chronic pancreatitis.
We focused our attention on this mutation because this is the
only natural PRSS1 variant that affects the substrate binding
site of trypsin. Specifically, the mutation alters the S2 subsite,
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Fig. 8. Effect of mutation p.L104P on cellular secretion of trypsinogen. HEK
293T cells were transiently transfected with expression plasmids for wild-type
and mutant human cationic trypsinogen, and conditioned media were collected
after 48 h. Trypsinogen protein levels were determined by Coomassie blue-
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a hydrophobic groove that imparts broad P2 specificity to
trypsin (9, 11). In addition, the main chain N of position 104
forms an H bond with position 100 that stabilizes the loop
between amino acids 97 and 107. Because Pro cannot act as an
H donor, the p.L104P mutation may destabilize the Pro97-
Asp107 loop and change the S2 site more profoundly and in a
somewhat unpredictable manner. Consistent with our predic-
tions of altered subsite specificity, we found that p.L104P
trypsin cleaved peptide and protein substrates with reduced
efficiency and bound the physiological trypsin inhibitor
SPINK1 with decreased affinity. There was no clear relation-
ship between the magnitude of the reduction in activity/binding
and the physicochemical properties of the P2 side chains, e.g.,
both CTRB1 and proCPA1 contain a Ser residue in the P2
position with respect to the activating peptide bond, yet tryp-
sin-mediated activation of CTRB1 was more severely impacted
by the p.L104P mutation (20-fold decrease) than activation of
proCPA1 (2-fold decrease). On the other hand, the p.L104P
mutant exhibited slightly increased autoactivation, indicating
that cleavage of the trypsinogen activation peptide by p.L104P
trypsin was somewhat improved. The P2 position in the
trypsinogen activation peptide corresponds to Asp22. Acidic
residues, Asp in particular, are not tolerated well in the other-
wise broadly specific S2 subsite of trypsin (21). Accordingly,
Asp22 serves as a critical inhibitor of trypsinogen autoactiva-
tion, and mutation of Asp22 to Gly (p.D22G) or Ala (p.D22A)
results in markedly accelerated autoactivation (13, 21). In case
of the p.L104P mutant, the altered S2 subsite seems to accom-
modate the P2 Asp22 slightly better, resulting in the small
increase in autoactivation.
Surprisingly, autoactivation of the p.L104P mutant was not
suppressed well by CTRC-mediated degradation, and the mu-
tant autoactivated to higher trypsin levels than wild-type
trypsinogen. Trypsinogen degradation requires CTRC-medi-
ated cleavage of the Leu81-Glu82 peptide bond in the calcium-
binding loop and a trypsin-mediated autolytic cleavage of the
Arg122-Val123 peptide bond (33, 38). The resistance of mutant
p.L104P trypsinogen to degradation during autoactivation was
due to slow cleavage at the Arg122 autolytic site, whereas
CTRC cleavage after Leu81 was unchanged.
The increased autoactivation of mutant p.L104P in the
presence of CTRC combined with its decreased inhibition by
SPINK1 should allow this variant to activate sooner and to
higher trypsin levels than its wild-type counterpart inside the
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Fig. 10. Endoplasmic reticulum stress markers in HEK 293T cells expressing
wild-type or p.L104P mutant trypsinogen. A: levels of immunoglobulin-
binding protein (BiP) mRNA were measured using quantitative reverse tran-
scription-PCR. B and C: splicing of X-box-binding protein 1 (XBP1) mRNA
was followed by reverse transcription-PCR using primers that amplify both the
spliced and unspliced species. Levels of spliced mRNA (XBP1s) were deter-
mined by densitometric analysis. Mean values  SD (n  5, each performed
in duplicate) are indicated. Significance was tested with 1-way analysis of
variance (P  0.0001) followed by Tukey-Kramer post hoc analysis (***P 
0.001). Representative agarose gel from five experiments is shown.
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pancreas. Although active p.L104P trypsin may not be as
harmful because of its defective cleavage of most protein
substrates, it can still promote autoactivation of wild-type
cationic trypsinogen produced from the wild-type allele in
heterozygous carriers. Thus, the biochemical basis for a poten-
tially strong pathogenic effect of the p.L104P mutation has
been identified. The caveat to this conclusion is that mutant
p.L104P needs to be produced and secreted to normal levels,
which turned out not to be the case.
Unexpectedly, we found that the p.L104P mutation caused
intracellular retention and aggregation of trypsinogen in trans-
fected 293T cells. Consistent with an interpretation of muta-
tion-induced misfolding, we observed elevated ER stress mark-
ers in cells expressing the p.L104P mutant. Thus, the dominant
effect of mutation p.L104P appears to be not biochemical but
cell biological. In other words, the mutation belongs to the
class of variants that act through the misfolding-dependent
pathway rather than the trypsin-dependent pathway. Although
the exact mechanism by which mutation p.L104P causes mis-
folding is not readily apparent, the loss of a potentially impor-
tant H bond that stabilizes the Pro97-Asp107 loop is likely a
contributing factor.
Mutation-induced misfolding and consequent perturbations
of ER homeostasis have been conclusively linked with chronic
pancreatitis. First, mutations p.R116C and p.C139S in PRSS1
were found to undergo misfolding with consequent ER stress,
suggesting that some trypsinogen variants might exert their
effects via a mechanism that is unrelated to trypsin activity
(14). This conclusion was later supported by analysis of 13 rare
PRSS1 variants presumed to cause pancreatitis (30). Among
these, five variants exhibited strong (p.D100H, p.C139F) or
moderate (p.K92N, p.S124F, p.G208A) secretion defects sug-
gestive of misfolding, although ER stress has not been studied.
It is interesting to note that misfolding PRSS1 variants were
typically found in cases of sporadic chronic pancreatitis with
no family history, suggesting a milder pathogenic effect rela-
tive to the trypsin-dependent high-penetrance mutations such
as p.R122H. Additional evidence for the role of misfolding in
chronic pancreatitis came from studies on the CPA1 gene that
demonstrated that loss-of-function CPA1 variants are associ-
ated with early onset disease and represent strong risk factors
(45). The majority of CPA1 variants found in patients exhibited
severely reduced cellular secretion due to intracellular reten-
tion and degradation. With the use of the relatively more
frequent p.N256K variant as a test case, strong ER stress was
demonstrated in AR42J acinar cells expressing mutant CPA1
(45). Besides PRSS1 and CPA1 mutations, some CTRC vari-
ants were also shown to result in misfolding and ER stress (1,
39). However, in contrast to trypsinogen and procarboxypep-
tidase that are produced in high abundance by the pancreas, the
lower expression levels of CTRC make it questionable whether
this mechanism is relevant to the pathogenic action of CTRC
variants. Similarly, misfolding SPINK1 variants are unlikely to
elicit ER stress due to low expression levels (4, 5, 18). More
recently, association of chronic pancreatitis with a novel du-
plicated hybrid allele of the CEL gene encoding carboxyl ester
lipase was described (12). Although not demonstrated experi-
mentally, it appears likely that this newly formed lipase mol-
ecule could also result in misfolding and ER stress. Finally, a
rare pancreatic triglyceride lipase (PNLIP) variant was found
in the homozygous state in two brothers with lipase deficiency
(2). Functional analysis revealed that the p.T221M variant
caused intracellular retention, loss of secretion, and strong ER
stress (36). Although a diagnosis of chronic pancreatitis has not
been established in the published carriers, signs of pancreatic
insufficiency have been documented, suggesting that ER
stress-related pathology may have contributed to their disease.
The mechanism by which ER stress increases risk for
chronic pancreatitis is not completely understood. Chronic
unresolved ER stress promotes apoptosis through upregulation
of the proapoptotic transcription factor CHOP, and this path-
way may contribute to parenchymal atrophy and subsequent
fibrosis (41, 48). Proinflammatory effects of ER stress have
been also documented. Thus, translational attenuation by
PERK-dependent eIF2 phosphorylation results in a relative
increase of NF-B vs. its inhibitor IB. Alternatively, NF-B
can be activated through degradation of IB as a result of the
recruitment and activation of IB kinase by the complex of
IRE1 and NF receptor-associated factor 2 (TRAF2). The IRE1-
TRAF2 complex can also activate the c-Jun NH2-terminal
kinase pathway leading to activator protein-1-mediated tran-
scriptional activation of proinflammatory genes (41, 48).
Whether or not these pathways are relevant to the development
of chronic pancreatitis remains to be determined.
In conclusion, the observations presented here argue that the
p.L104P variant of human cationic trypsinogen increases risk
for chronic pancreatitis primarily through misfolding and ER
stress. Although biochemical changes also indicate a strong
propensity for increased trypsinogen activation, the secretion
defect secondary to misfolding would diminish a trypsin-
dependent pathogenic effect.
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